Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States

Dominick Latremouille-ViauAnalysis Group, Inc., Montreal, QC, Canada; Correspondence[email protected]

Annie GuerinAnalysis Group, Inc., Montreal, QC, Canada;

Roy NitulescuAnalysis Group, Inc., Montreal, QC, Canada;

Patrick S. GagnonAnalysis Group, Inc., Montreal, QC, Canada;

George J. JosephNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Lei ChenNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sinan Mersin, Fatih Gülük, Emirhan Gülcan & Ahmet Emre Eşkazan. (2023) Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults. Expert Opinion on Pharmacotherapy 24:15, pages 1703-1713.
Read now

Articles from other publishers (6)

Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2.
Crossref

Ehab Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Wu & Pallavi Patwardhan. (2022) Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Journal of Health Economics and Outcomes Research 9:2, pages 19-29.
Crossref

Chi‐Jung Tai, Chin‐Chung Wu, Kun‐Tai Lee, Tzyy‐Guey Tseng, Hui‐Chun Wang, Fang‐Rong Chang & Yi‐Hsin Yang. (2021) The Impact of Urate‐Lowering Therapy in Post‐Myocardial Infarction Patients: Insights From a Population‐Based, Propensity Score‐Matched Analysis. Clinical Pharmacology & Therapeutics 111:3, pages 655-663.
Crossref

Julia F. SlejkoJuan-David RuedaJames A. TrovatoEmily F. GormanGail BetzStephen ArconaChristopher ZackerBruce Stuart. (2019) A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1125-1132.
Crossref

Kelly M. Kenzik, Ravi Bhatia, Grant R. Williams & Smita Bhatia. (2019) Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer.
Crossref

Karen Seiter, Dominick Latremouille-Viau, Annie Guerin, Briana Ndife, Karen Habucky, Derek H. Tang, Irina Pivneva, Patrick Gagnon-Sanschagrin & George J. Joseph. (2018) Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy 35:10, pages 1671-1685.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States

Citations (7)

Read on this site (1)

Articles from other publishers (6)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date